World Journal of Advanced Pharmaceutical and Medical Research

Journal homepage: https://zealjournals.com/wjapmr/

ISSN: 2799-0656 (Online)

(REVIEW ARTICLE)

Check for updates

Pharmacogenomic approaches for tailoring medication to genetic profiles in diverse populations

Adeola Feyisitan Banji [1], Adeleke Damilola Adekola [2,*] and Samuel Ajibola Dada [2]

[1] *Independent Researcher, Lagos, Nigeria.*
[2] *Syracuse University, NY, USA.*

World Journal of Advanced Pharmaceutical and Medical Research, 2024, 07(02), 109–118

Publication history: Received on 07 October 2024; revised on 14 November 2024; accepted on 17 November 2024

Article DOI: https://doi.org/10.53346/wjapmr.2024.7.2.0049

Abstract

Pharmacogenomics, a branch of precision medicine, focuses on how genetic variations influence individual responses to drugs, allowing for more tailored and effective treatments. This approach has the potential to significantly enhance therapeutic outcomes by improving drug efficacy, minimizing adverse reactions, and optimizing medication use. By considering genetic makeup, pharmacogenomic strategies enable healthcare providers to personalize treatments for patients, particularly in the management of complex conditions like cancer, cardiovascular diseases, and mental health disorders. However, pharmacogenomics must be applied equitably across all populations to reach its full potential. Inclusive research and comprehensive policies are crucial in addressing disparities in access to pharmacogenomic testing and therapies, particularly for underrepresented and marginalized communities. This paper discusses the importance of advancing pharmacogenomic approaches in personalized medicine, emphasizing the need for diverse research and equitable access to ensure that these innovations benefit all patients.

Keywords: Pharmacogenomics; Precision medicine; Personalized treatment; Health equity; Genetic testing

1. Introduction

Pharmacogenomics is an evolving field at the intersection of pharmacology and genomics that seeks to understand how an individual's genetic makeup influences their response to drugs. This branch of science supports the concept of personalized medicine, where treatment regimens are tailored to each patient's genetic profile to enhance efficacy and minimize adverse reactions (Balogun et al., 2024). Unlike the traditional "one-size-fits-all" approach, pharmacogenomics enables healthcare providers to prescribe medications that are specifically suited to an individual's genetic characteristics (Hayashi, Hamdy, & Mahmoud, 2022). For example, genetic variations can influence drug metabolism rates, enhancing or diminishing therapeutic effects. Such insights into genetic variability pave the way for more precise and effective medical treatments (Pirmohamed, 2023).

Genetic variability is pivotal in determining how individuals process and respond to medications. Differences in genes, such as those encoding for drug-metabolizing enzymes (e.g., the CYP450 family), transport proteins, or receptors, can significantly impact drug efficacy and safety (Zhao et al., 2021). Understanding these genetic distinctions is crucial for mitigating adverse drug reactions (ADRs) and optimizing therapeutic outcomes. For instance, patients with genetic polymorphisms that affect the enzyme CYP2D6 may metabolize certain antidepressants or opioids too quickly or too slowly, leading to treatment failure or toxic side effects (Jin & Zhong, 2023). Hence, appreciating these genetic differences ensures that medication regimens are more effective and safer for individual patients.

Despite significant advancements in pharmacogenomics, much of the research to date has primarily focused on populations of European descent (Takeuchi et al., 2020). This lack of diversity in genomic studies presents a critical gap,

* Corresponding author: Adeleke Damilola Adekola

as genetic variability can differ widely between ethnic groups, affecting the accuracy and applicability of pharmacogenomic findings. For instance, allelic frequencies for drug-metabolizing enzymes like CYP2C9 and VKORC1 vary across different populations, which can lead to disparities in drug responses (Sambyalova et al., 2020). Addressing these gaps is essential for promoting health equity and ensuring that the benefits of pharmacogenomic research are accessible to all, not just a subset of the population. By including a wider range of genetic backgrounds in research, healthcare providers can develop more comprehensive and inclusive strategies for precision medicine (Ibikunle et al., 2024b).

The primary aim of this paper is to explore how pharmacogenomic approaches can be leveraged to tailor medications to the genetic profiles of individuals from diverse populations. The discussion will emphasize the scientific principles underpinning pharmacogenomics, highlight existing challenges in implementing such strategies across varied demographic groups, and outline the potential benefits and opportunities these approaches present. Additionally, the paper will address the ethical, legal, and social considerations accompanying genetic profiling integration into clinical practice.

This focus is particularly relevant given the ongoing pursuit of more equitable healthcare systems. The COVID-19 pandemic has underscored the disparities in health outcomes experienced by different demographic groups, reinforcing the need for more inclusive research and personalized treatment approaches. By tailoring pharmacogenomic strategies to diverse populations, healthcare systems can enhance therapeutic efficacy, reduce the incidence of ADRs, and promote better overall patient outcomes. This paper, therefore, aims to shed light on the importance of expanding pharmacogenomic research to include underrepresented populations, ensuring that the advancements in personalized medicine contribute to global health equity.

2. The Scientific Basis of Pharmacogenomics

Pharmacogenomics is grounded in understanding how genetic components, such as genes and alleles, affect drug metabolism and response. Genes are DNA sequences responsible for coding proteins, many of which are involved in drug metabolism processes (van der Lee, Kriek, Guchelaar, & Swen, 2020). Alleles are variations in these gene sequences that can alter the function or production of the proteins they encode. Such variations can lead to differences in how individuals absorb, distribute, metabolize, and excrete medications, which impacts both their efficacy and safety (Wright, Smith, & Jiggins, 2022).

A significant focus within pharmacogenomics is on enzymes that metabolize drugs, such as those in the cytochrome P450 (CYP450) enzyme family. For instance, genetic variations in the CYP2D6 gene can result in individuals being categorized as poor, intermediate, extensive, or ultra-rapid metabolizers (Taylor et al., 2020). This classification is vital because poor metabolizers may experience drug accumulation and potential toxicity, whereas ultra-rapid metabolizers may not achieve the desired therapeutic effect due to rapid drug clearance. Such genetic diversity necessitates personalized medication strategies to ensure optimal dosing and minimize adverse effects (Alchakee, Ahmed, Eldohaji, Alhaj, & Saber-Ayad, 2022).

Genetic polymorphisms are key to understanding the inter-individual variability in drug response. Pharmacokinetics, which deals with the movement of drugs through the body, can be affected by polymorphisms in genes encoding drug-metabolizing enzymes. (Langmia et al., 2021) One example is the CYP2C19 gene, which influences the metabolism of drugs like clopidogrel and proton pump inhibitors. Individuals with certain polymorphisms in CYP2C19 may exhibit poor or ultra-rapid metabolism, leading to suboptimal drug efficacy or an increased risk of side effects (Shubbar et al., 2024).

Pharmacodynamic polymorphisms, on the other hand, involve genetic variations that affect drug targets or the biological pathways they influence. The VKORC1 gene, which affects sensitivity to warfarin, is a notable example (Bach-Rojecky, Primorac, Topić, Štefanović, & Höppner, 2024). Variants in VKORC1 can dictate the amount of warfarin required to achieve anticoagulation without excessive bleeding risks. Additionally, polymorphisms in the SLCO1B1 gene, encoding a transporter protein, can impact the uptake and clearance of statins. Variants in SLCO1B1 are associated with a higher risk of statin-induced myopathy, making genetic testing an important consideration before initiating statin therapy (Ndadza, 2023).

The CYP450 enzyme family, particularly CYP2D6, CYP2C9, and CYP2C19, has been extensively studied in the field of pharmacogenomics. These enzymes are responsible for metabolizing a significant proportion of drugs (Taylor et al., 2020). For example, approximately 20% of all drugs are metabolized by CYP2D6, including antidepressants, beta-

blockers, and certain opioids. Individuals with inactive or duplicated CYP2D6 alleles may need adjusted dosages or alternative medications to achieve optimal treatment outcomes (Waring, 2020).

SLCO1B1 is another prominent genetic marker in pharmacogenomic research. This gene encodes for an organic anion-transporting polypeptide involved in the hepatic uptake of drugs such as statins. Variants in SLCO1B1 can lead to reduced transporter function, which increases the concentration of statins in the bloodstream and raises the risk of muscle-related side effects. Understanding these variants enables healthcare providers to personalize statin prescriptions, improving patient safety and effectiveness (Ahangari et al., 2020).

These examples illustrate the importance of genetic markers in informing clinical decisions. The integration of pharmacogenomic knowledge into clinical practice allows for more precise and patient-centered approaches to medication management, ultimately enhancing the effectiveness of treatment plans and reducing the risk of adverse drug reactions.

3. Challenges in Implementing Pharmacogenomic Strategies Across Diverse Populations

3.1. Limited Representation of Certain Ethnic Groups in Genetic Research

A significant challenge in pharmacogenomics is the underrepresentation of diverse ethnic groups in genetic research. Most studies have predominantly focused on populations of European descent, resulting in a knowledge gap when it comes to understanding genetic variability in other groups (Magavern, Gurdasani, Ng, & Lee, 2022). This lack of representation can lead to biased data and the development of pharmacogenomic tests that are less applicable to non-European populations. Consequently, healthcare providers may struggle to make accurate, evidence-based decisions for individuals from underrepresented groups, ultimately limiting the effectiveness of personalized medicine (Luczak, Stenehjem, & Brown, 2021).

The underrepresentation in research stems from historical, socioeconomic, and logistical factors that have limited the participation of diverse populations. Addressing this imbalance requires targeted efforts to include a wider range of ethnic backgrounds in genomic studies. This would enhance the generalizability of pharmacogenomic findings and contribute to more equitable healthcare outcomes.

3.2. Variability in Genetic Data and Implications for Drug Development

Genetic variability across populations challenges the development of universal pharmacogenomic strategies. Different populations may have unique allele frequencies, which can affect the metabolism and efficacy of certain medications. For instance, polymorphisms in the CYP2D6 gene are known to vary significantly between ethnic groups, with certain alleles being more prevalent in specific populations. This variability can lead to different drug responses and adverse reaction profiles (Chenoweth et al., 2020).

The implications for drug development are profound. Pharmaceutical companies may need to adapt their clinical trials to consider genetic diversity explicitly. Failure to do so can result in drugs that are less effective or pose greater risks for specific groups. This also raises the importance of including diverse populations in clinical trials and post-market surveillance to understand the full range of potential drug responses (Al-Worafi, 2023).

3.3. Socioeconomic and Infrastructural Barriers to Widespread Adoption of Pharmacogenomic Testing

Socioeconomic and infrastructural challenges often hinder the widespread adoption of pharmacogenomic testing. High costs associated with genetic testing can make these services inaccessible to lower-income populations (L Rogers et al., 2020). Without adequate insurance coverage or government subsidies, many individuals are unable to benefit from personalized medication strategies. Additionally, healthcare providers in resource-limited settings may lack the necessary infrastructure or training to incorporate pharmacogenomic information into their practice (Koufaki et al., 2021).

Educational barriers further complicate the implementation of pharmacogenomic strategies. Clinicians may not be sufficiently trained in interpreting genetic test results, which limits their ability to use this information effectively in treatment planning. Addressing these barriers requires coordinated efforts involving healthcare policymakers, educators, and industry stakeholders to ensure that pharmacogenomic advancements are both accessible and actionable across all segments of society (Pinzón-Espinosa et al., 2022).

Infrastructure plays a critical role in the integration of pharmacogenomics into standard practice. In many parts of the world, healthcare systems lack the technological capabilities to securely store and process large volumes of genetic data. Investments in electronic health records and data management solutions are essential to support the widespread use of genetic information in clinical settings (Udegbe, Ebulue, Ebulue, & Ekesiobi, 2024). Bridging these socioeconomic and infrastructural gaps will be key to achieving equitable implementation of pharmacogenomic strategies. Collaborative initiatives between governments, private organizations, and international bodies can help create a supportive framework that facilitates the adoption of personalized medicine across diverse populations (Malik et al., 2025).

In summary, while pharmacogenomics holds immense promise for improving drug efficacy and safety, challenges related to representation, genetic variability, and systemic barriers must be addressed to ensure that its benefits are realized equitably. Tailoring solutions that acknowledge and address these challenges is essential for the effective integration of pharmacogenomic strategies into global healthcare.

4. Benefits and Opportunities in Personalized Medicine

Personalized medicine, which tailors medical treatments to the individual characteristics of each patient, is increasingly being seen as a transformative approach in healthcare. This paradigm shift offers multiple benefits and opportunities, particularly in improving therapeutic outcomes, reducing adverse drug reactions, enhancing equity in healthcare, and making genetic profiling more accessible through technological advancements.

4.1. Improved Therapeutic Outcomes Through Targeted Drug Therapies

One of the most significant benefits of personalized medicine is its ability to improve therapeutic outcomes by using targeted drug therapies. Traditional medicine often relies on a "one-size-fits-all" approach, where drugs are prescribed based on general guidelines that may not account for individual differences in genetics, environment, or lifestyle. In contrast, personalized medicine considers these factors, allowing for more precise treatment plans (Gambardella et al., 2020).

By analyzing a patient's genetic makeup, physicians can select drugs that are more likely to be effective for that specific individual. For instance, genetic testing can reveal how a patient's body metabolizes certain drugs, which can inform the dosage and type of medication prescribed. This can lead to quicker recovery times, greater treatment effectiveness, and the ability to avoid unnecessary or ineffective treatments. Personalized therapies, especially in oncology, have shown remarkable promise (Ibikunle et al., 2024b). For example, targeted cancer therapies, which focus on specific genetic mutations within cancer cells, have improved survival rates in patients with conditions like breast cancer and lung cancer. Moreover, personalized medicine increases the likelihood of success and enables ongoing adjustments to treatment as the patient's condition evolves. Continuous genetic and molecular testing throughout treatment can ensure that the prescribed drugs remain optimal, leading to better long-term health outcomes (Manzari et al., 2021).

4.2. Potential Reduction in Adverse Drug Reactions

Another major advantage of personalized medicine is its potential to reduce adverse drug reactions (ADRs), which are a common cause of morbidity and mortality worldwide. Traditional approaches to prescribing medications often do not consider how genetic variations can affect a patient's response to a drug. For example, some patients may experience severe side effects because their genetic profile makes them metabolize the drug too quickly or too slowly, leading to toxic effects or insufficient efficacy (Micaglio et al., 2021).

Through genetic testing, healthcare providers can predict how a patient will react to a particular drug before it is prescribed. This can help identify patients who are at higher risk for ADRs, allowing physicians to choose medications that are safer for them or adjust the dosage accordingly (Montané & Santesmases, 2020). For example, certain genetic variations can indicate a higher risk of cardiovascular events when using specific painkillers, or they may suggest that a patient would respond better to a different class of antidepressants. By reducing the occurrence of ADRs, personalized medicine not only improves patient safety but also enhances the overall efficiency of healthcare systems by preventing the need for costly emergency interventions, hospitalizations, or long-term health complications related to adverse drug effects (Pardiñas, Owen, & Walters, 2021).

4.3. Enhancing Equity in Healthcare by Tailoring Interventions to Underrepresented Populations

Personalized medicine has the potential to foster greater equity in healthcare by tailoring interventions to meet the unique needs of underrepresented populations. Historically, medical research has often been conducted on homogeneous groups, leading to gaps in knowledge when it comes to how various ethnicities and subgroups respond

to treatment. Personalized medicine aims to bridge this gap by providing more inclusive data that can inform better health interventions (Tawfik et al., 2023).

By incorporating genetic information from diverse populations, personalized medicine can help identify health risks and treatment responses specific to different groups. This approach ensures that medical treatments are more accurately matched to the individual's genetic background, lifestyle, and environmental factors. For instance, certain ethnic groups may have genetic predispositions to specific conditions, such as sickle cell disease in African populations or lactose intolerance in East Asian populations (Geneviève, Martani, Shaw, Elger, & Wangmo, 2020). Personalized treatment plans can address these disparities by considering these factors in drug design and healthcare interventions. Furthermore, by utilizing data from historically underrepresented populations, personalized medicine can help reduce healthcare disparities. This makes it possible to provide more equitable healthcare solutions that improve access to treatments and reduce the impact of social determinants of health on patient outcomes (Washington, Franklin, Huang, Mega, & Abernethy, 2023).

4.4. Advancements in Technology Enabling Broader Access to Genetic Profiling

The ongoing advancements in technology have played a crucial role in making genetic profiling more accessible, which in turn expands the potential of personalized medicine. In the past, genetic testing and genomic sequencing were prohibitively expensive and limited to specialized research settings. However, technological breakthroughs in sequencing technologies, such as next-generation sequencing (NGS), have significantly reduced the cost and time required for genetic analysis (Satam et al., 2023).

As a result, genetic profiling has become more accessible to the broader population. The advent of consumer-facing genetic testing companies, such as 23andMe and AncestryDNA, has introduced the general public to genetic information, sparking interest in personalized healthcare. Healthcare providers are increasingly using genetic testing to inform clinical decision (Cohen, Farahany, Greely, & Shachar, 2021) s. Genetic tests are now being used not just for rare genetic disorders but also for more common conditions, including cardiovascular diseases, diabetes, and mental health disorders. Moreover, advancements in artificial intelligence (AI) and machine learning are enhancing the analysis of genetic data. These technologies enable processing vast amounts of data to uncover patterns that would otherwise be difficult to detect. This is accelerating the development of personalized treatments that can be tailored to an individual's genetic profile with greater precision (Kumar, Cowley, & Davis, 2024).

In addition, improvements in telemedicine and digital health tools are expanding access to genetic testing in remote or underserved areas. Patients no longer need to travel long distances to specialized centers to undergo testing. Through online consultations and at-home genetic testing kits, individuals can obtain crucial genetic information that can guide their healthcare decisions. These technological advancements make personalized medicine more accessible and affordable, helping to level the playing field for patients regardless of location or socioeconomic status (Barbosa, Zhou, Waddell, Myers, & Dorsey, 2021).

5. Ethical, Legal, and Social Considerations in Personalized Medicine

5.1. Addressing Privacy Concerns Related to Genetic Data

One of the most pressing ethical concerns in personalized medicine is the privacy of genetic data. Genetic information is inherently sensitive, as it contains not only personal health information but also insights into an individual's family history and potential future health risks. Because this data is so personal, its misuse or unauthorized access can have severe consequences, including genetic discrimination, stigmatization, or social exclusion (Winkler & Knoppers, 2022).

Genetic data collection, storage, and sharing must be subject to strict privacy protections. In many countries, laws like the Health Insurance Portability and Accountability Act (HIPAA) in the United States aim to ensure the confidentiality of health information. However, as genetic data becomes more integrated into healthcare, there are concerns about how to protect it against breaches or misuse, especially when shared across multiple platforms or institutions. One major risk is that genetic data may be used by third parties, such as insurance companies, employers, or law enforcement, to discriminate against individuals based on their genetic predispositions, despite legal protections (Chapman, Mehta, Parent, & Caplan, 2020).

Moreover, the rise of direct-to-consumer genetic testing companies raises additional privacy risks. Consumers may unknowingly expose their genetic data to commercial interests, such as marketing firms or research entities, which may not be fully transparent about how they use or share the data. Clear policies and guidelines around collecting, storing,

and using genetic data are critical in ensuring that individuals' privacy is respected and protected (Maeckelberghe, Zdunek, Marceglia, Farsides, & Rigby, 2023).

5.2. Ensuring Informed Consent and Understanding Among Patients

Informed consent is a fundamental ethical principle in healthcare, and its application in personalized medicine is especially important. Patients must fully understand the potential risks and benefits of genetic testing and how the resulting information will be used. This includes understanding how their genetic data will impact their treatment plans and the potential implications for their families and future generations (Erdmann, Rehmann-Sutter, & Bozzaro, 2021).

However, the complexity of genetic information can make it difficult for many patients to grasp the full scope of what is involved in genetic testing. Genetic counseling is essential in helping patients understand the potential outcomes of testing and the implications for their health. While genetic testing can offer valuable insights into an individual's predisposition to certain conditions, patients may not always be aware of the emotional, psychological, or social consequences of receiving such information (Claussnitzer et al., 2020).

Moreover, obtaining informed consent is not simply a one-time procedure but an ongoing process. As genetic research and technologies evolve, so too do how genetic data is interpreted and used. This means that patients may need to consent to use their data multiple times throughout their lives, and they should be kept informed of any new developments that could affect them. Ensuring clear, accessible communication about these aspects of personalized medicine is crucial in respecting patient autonomy and ensuring that individuals are truly informed about their decisions (Kwok, Mentzer, & Knight, 2021).

5.3. Challenges Related to Data Ownership and Ethical Use

The question of who owns genetic data is a significant ethical issue in personalized medicine. Genetic data is often collected by healthcare providers, researchers, or genetic testing companies, but the question of ownership and control over this information remains ambiguous. Patients may feel that their genetic data belongs to them, but once the data is collected, it may be used by others for research or commercial purposes. This creates a tension between individual rights and the broader societal benefits that genetic data can provide (Amorim et al., 2022).

From an ethical standpoint, it is important to ensure that genetic data is used responsibly. Researchers and companies may seek to use this data to improve public health or develop new treatments, but patients need assurances that their data will be used ethically and not exploited for commercial gain. Consent should extend beyond initial testing and involve transparency about how data will be used, stored, and shared. This includes whether genetic data will be anonymized, how long it will be kept, and whether patients can withdraw their consent.

Furthermore, as genetic data becomes an increasingly valuable asset in research and drug development, there is concern about the potential for exploitation, particularly among vulnerable populations. Ethical guidelines must be established to ensure that individuals are not coerced into providing their genetic data, particularly when they are part of underserved or marginalized groups. Ensuring fair compensation, access, and benefit-sharing in research is essential in maintaining public trust in personalized medicine (Bonomi, Huang, & Ohno-Machado, 2020).

While personalized medicine is promising to improve healthcare, it also raises concerns about discrimination and bias. The potential for genetic data to be used inappropriately, such as for employment or insurance decisions, poses risks for individuals, particularly those with genetic predispositions to certain conditions. For instance, an employer may be hesitant to hire someone based on their genetic risk for developing a chronic illness, or an insurance company might use genetic data to deny coverage for individuals with a genetic predisposition to expensive conditions (Abass et al., 2024).

To address these concerns, many countries have implemented laws that prohibit genetic discrimination, such as the Genetic Information Nondiscrimination Act (GINA) in the U.S. However, gaps still remain in ensuring that genetic data is protected in all contexts. For example, GINA does not cover life insurance, disability insurance, or long-term care insurance, which may leave certain individuals vulnerable to discrimination (Ibikunle et al., 2024a; Kelvin-Agwu, Adelodun, Igwama, & Anyanwu, 2024b).

Additionally, bias in genetic research and healthcare practices can contribute to disparities in how personalized medicine is applied. The majority of genetic research has historically focused on individuals of European descent, leading to a lack of representation of diverse populations in genomic databases. This can result in less accurate predictions and recommendations for non-European populations, exacerbating existing health inequities. To overcome

this, there needs to be a concerted effort to include diverse populations in genetic research and to ensure that healthcare providers are trained to recognize and address biases that may affect the application of personalized treatments. As innovation in personalized medicine progresses, it is crucial to maintain a careful balance between advancing medical science and safeguarding against the potential harms of genetic data misuse. Policymakers, healthcare providers, and researchers must work together to develop frameworks that promote innovation while protecting individual rights and ensuring fairness across populations (Kelvin-Agwu, Adelodun, Igwama, & Anyanwu, 2024a; Usuemerai et al., 2024).

6. Conclusion

Pharmacogenomics, the study of how genetic variations influence individual drug responses, is crucial in advancing precision medicine. By integrating genetic information into medical treatment plans, pharmacogenomic approaches enable healthcare providers to tailor therapies to the unique genetic makeup of each patient. This personalized approach significantly enhances therapeutic outcomes, minimizes adverse drug reactions, and optimizes the use of medications, ensuring that patients receive the most effective treatment based on their genetic profile. In the context of diseases like cancer, cardiovascular conditions, and mental health disorders, pharmacogenomics allows for more targeted and efficient treatments, improving patient health and contributing to better overall healthcare outcomes.

However, the full potential of pharmacogenomics can only be realized if the field is expanded and made accessible to all populations, particularly underrepresented and marginalized groups. The ongoing advancements in genomic technology and research are making personalized treatments increasingly viable; yet, the benefits of pharmacogenomics must be coupled with efforts to ensure that these innovations are applied equitably across diverse populations. A lack of inclusive research, particularly involving ethnic minorities and underserved communities, may perpetuate health disparities and limit the generalizability of pharmacogenomic strategies.

To achieve this, it is essential to prioritize inclusive and diverse research in pharmacogenomics. This includes conducting studies that represent a broad spectrum of genetic backgrounds to ensure that the benefits of precision medicine extend beyond historically studied groups. Additionally, it is vital to establish policies that promote equitable access to pharmacogenomic testing and treatments. This involves addressing issues such as cost, healthcare infrastructure, and insurance coverage to ensure that all individuals, regardless of socioeconomic status or geographic location, can benefit from advancements in personalized medicine.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed

References

[1] Abass, L. A., Usuemerai, P. A., Ibikunle, O. E., Alemede, V., Nwankwo, E. I., & Mbata, A. O. (2024). Enhancing patient engagement through CRM systems: A pathway to improved healthcare delivery. International Medical Science Research Journal, 4(10), 928-960. doi:https://doi.org/10.51594/imsrj.v4i10.1648

[2] Ahangari, N., Doosti, M., Ghayour Mobarhan, M., Sahebkar, A., Ferns, G. A., & Pasdar, A. (2020). Personalised medicine in hypercholesterolaemia: The role of pharmacogenetics in statin therapy. Annals of medicine, 52(8), 462-470.

[3] Al-Worafi, Y. M. (2023). Pharmacogenomics in Developing Countries. In Handbook of Medical and Health Sciences in Developing Countries: Education, Practice, and Research (pp. 1-37): Springer.

[4] Alchakee, A., Ahmed, M., Eldohaji, L., Alhaj, H., & Saber-Ayad, M. (2022). Pharmacogenomics in psychiatry practice: the value and the challenges. International journal of molecular sciences, 23(21), 13485.

[5] Amorim, M., Silva, S., Machado, H., Teles, E. L., Baptista, M. J., Maia, T., . . . de Freitas, C. (2022). Benefits and risks of sharing genomic data for research: comparing the views of rare disease patients, informal carers and healthcare professionals. International Journal of Environmental Research and Public Health, 19(14), 8788.

[6] Bach-Rojecky, L., Primorac, D., Topić, E., Štefanović, M., & Höppner, W. (2024). Role of Drug Targets and Other Proteins Important in Pharmacogenomics. In Pharmacogenomics in Clinical Practice (pp. 89-104): Springer.

[7] Balogun, O. D., Ayo-Farai, O., Ogundairo, O., Maduka, C. P., Okongwu, C. C., Babarinde, A. O., & Sodamade, O. T. (2024). The role of pharmacists in personalised medicine: a review of integrating pharmacogenomics into clinical practice. International Medical Science Research Journal, 4(1), 19-36.

[8] Barbosa, W., Zhou, K., Waddell, E., Myers, T., & Dorsey, E. R. (2021). Improving access to care: telemedicine across medical domains. Annual review of public health, 42(1), 463-481.

[9] Bonomi, L., Huang, Y., & Ohno-Machado, L. (2020). Privacy challenges and research opportunities for genomic data sharing. Nature genetics, 52(7), 646-654.

[10] Chapman, C. R., Mehta, K. S., Parent, B., & Caplan, A. L. (2020). Genetic discrimination: emerging ethical challenges in the context of advancing technology. Journal of Law and the Biosciences, 7(1), lsz016.

[11] Chenoweth, M. J., Giacomini, K. M., Pirmohamed, M., Hill, S. L., van Schaik, R. H., Schwab, M., . . . Tyndale, R. F. (2020). Global pharmacogenomics within precision medicine: challenges and opportunities. Clinical Pharmacology & Therapeutics, 107(1), 57-61.

[12] Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., . . . MacArthur, D. G. (2020). A brief history of human disease genetics. Nature, 577(7789), 179-189.

[13] Cohen, I. G., Farahany, N. A., Greely, H. T., & Shachar, C. (2021). Consumer genetic technologies: ethical and legal considerations: Cambridge University Press.

[14] Erdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021). Patients' and professionals' views related to ethical issues in precision medicine: a mixed research synthesis. BMC Medical Ethics, 22(1), 116.

[15] Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., . . . Cervantes, A. (2020). Personalized medicine: recent progress in cancer therapy. *Cancers, 12*(4), 1009.

[16] Geneviève, L. D., Martani, A., Shaw, D., Elger, B. S., & Wangmo, T. (2020). Structural racism in precision medicine: leaving no one behind. BMC Medical Ethics, 21, 1-13.

[17] Hayashi, M., Hamdy, D. A., & Mahmoud, S. H. (2022). Applications for pharmacogenomics in pharmacy practice: A scoping review. Research in Social and Administrative Pharmacy, 18(7), 3094-3118.

[18] Ibikunle, O. E., Usuemerai, P. A., Abass, L. A., Alemede, V., Nwankwo, E. I., & Mbata, A. O. (2024a). AI and digital health innovation in pharmaceutical development. Computer Science & IT Research Journal, 5(10), 2301-2340. doi:https://doi.org/10.51594/csitrj.v5i10.1649

[19] Ibikunle, O. E., Usuemerai, P. A., Abass, L. A., Alemede, V., Nwankwo, E. I., & Mbata, A. O. (2024b). Artificial intelligence in healthcare forecasting: Enhancing market strategy with predictive analytics. International Journal of Applied Research in Social Sciences, 6(10), 2409–2446. doi: https://doi.org/10.51594/ijarss.v6i10.1640

[20] Jin, J., & Zhong, X.-b. (2023). Epigenetic mechanisms contribute to intraindividual variations of drug metabolism mediated by cytochrome P450 enzymes. Drug Metabolism and Disposition, 51(6), 672-684.

[21] Kelvin-Agwu, M. C., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024a). Advancements in biomedical device implants: A comprehensive review of current technologies.

[22] Kelvin-Agwu, M. C., Adelodun, M. O., Igwama, G. T., & Anyanwu, E. C. (2024b). Strategies For Optimizing The Management Of Medical Equipment In Large Healthcare Institutions. Strategies, 20(9), 162-170.

[23] Koufaki, M.-I., Karamperis, K., Vitsa, P., Vasileiou, K., Patrinos, G. P., & Mitropoulou, C. (2021). Adoption of pharmacogenomic testing: a marketing perspective. Frontiers in Pharmacology, 12, 724311.

[24] Kumar, K. R., Cowley, M. J., & Davis, R. L. (2024). Next-generation sequencing and emerging technologies. Paper presented at the Seminars in thrombosis and hemostasis.

[25] Kwok, A. J., Mentzer, A., & Knight, J. C. (2021). Host genetics and infectious disease: new tools, insights and translational opportunities. Nature Reviews Genetics, 22(3), 137-153.

[26] L Rogers, S., Keeling, N. J., Giri, J., Gonzaludo, N., Jones, J. S., Glogowski, E., & Formea, C. M. (2020). PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing. Pharmacogenomics, 21(11), 785-796.

[27] Langmia, I. M., Just, K. S., Yamoune, S., Brockmöller, J., Masimirembwa, C., & Stingl, J. C. (2021). CYP2B6 functional variability in drug metabolism and exposure across populations—implication for drug safety, dosing, and individualized therapy. Frontiers in genetics, 12, 692234.

[28] Luczak, T., Stenehjem, D., & Brown, J. (2021). Applying an equity lens to pharmacogenetic research and translation to under-represented populations. Clinical and translational science, 14(6), 2117-2123.

[29] Maeckelberghe, E., Zdunek, K., Marceglia, S., Farsides, B., & Rigby, M. (2023). The ethical challenges of personalized digital health. Frontiers in Medicine, 10, 1123863.

[30] Magavern, E. F., Gurdasani, D., Ng, F. L., & Lee, S. S. J. (2022). Health equality, race and pharmacogenomics. British journal of clinical pharmacology, 88(1), 27-33.

[31] Malik, K., Upreti, K., Chaudhary, A., Kumar, N., Singh, O., & Tharewal, S. (2025). Integrating Telemedicine Into Population Health Management for Pharmacogenomics and Patient-Centered Care in Rural India. In Convergence of Population Health Management, Pharmacogenomics, and Patient-Centered Care (pp. 169-190): IGI Global.

[32] Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021). Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 6(4), 351-370.

[33] Micaglio, E., Locati, E. T., Monasky, M. M., Romani, F., Heilbron, F., & Pappone, C. (2021). Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Frontiers in Pharmacology, 12, 651720.

[34] Montané, E., & Santesmases, J. (2020). Adverse drug reactions. Medicina Clínica (English Edition), 154(5), 178-184.

[35] Ndadza, A. (2023). Pharmacogenomics of warfarin: comprehensive evaluation of important warfarin genomic response factors.

[36] Pardiñas, A. F., Owen, M. J., & Walters, J. T. (2021). Pharmacogenomics: A road ahead for precision medicine in psychiatry. Neuron, 109(24), 3914-3929.

[37] Pinzón-Espinosa, J., van der Horst, M., Zinkstok, J., Austin, J., Aalfs, C., Batalla, A., . . . Luykx, J. J. (2022). Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe. Translational psychiatry, 12(1), 442.

[38] Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 24(6), 350-362.

[39] Sambyalova, A. Y., Bairova, T., Belyaeva, E., Ershova, O., Sargaeva, D., & Kolesnikov, S. (2020). CYP2C9, CYP4F2, VKORC1 gene polymorphism in Buryat population. Russian Journal of Genetics, 56, 1496-1503.

[40] Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., . . . Das, G. (2023). Next-generation sequencing technology: current trends and advancements. Biology, 12(7), 997.

[41] Shubbar, Q., Alchakee, A., Issa, K. W., Adi, A. J., Shorbagi, A. I., & Saber-Ayad, M. (2024). From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Frontiers in Pharmacology, 15, 1326776.

[42] Takeuchi, M., Kobayashi, T., Biss, T., Kamali, F., Vear, S. I., Ho, R. H., . . . Carleton, B. C. (2020). CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. The Pharmacogenomics Journal, 20(2), 306-319.

[43] Tawfik, S. M., Elhosseiny, A. A., Galal, A. A., William, M. B., Qansuwa, E., Elbaz, R. M., & Salama, M. (2023). Health inequity in genomic personalized medicine in underrepresented populations: a look at the current evidence. *Functional & Integrative Genomics, 23*(1), 54.

[44] Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020). A Review of the Important Role of CYP2D6 in Pharmacogenomics. *Genes, 11*(11), 1295.

[45] Udegbe, F. C., Ebulue, O. R., Ebulue, C. C., & Ekesiobi, C. S. (2024). Precision Medicine and Genomics: A comprehensive review of IT-enabled approaches. *International Medical Science Research Journal, 4*(4), 509-520.

[46] Usuemerai, P. A., Ibikunle, O. E., Abass, L. A., Alemede, V., Nwankwo, E. I., & Mbata, A. O. (2024). Advanced supply chain optimization for emerging market healthcare systems. *International Journal of Management & Entrepreneurship Research, 6*(10), 3321–3356. doi:https://doi.org/10.51594/ijmer.v6i10.1637

[47] van der Lee, M., Kriek, M., Guchelaar, H.-J., & Swen, J. J. (2020). Technologies for pharmacogenomics: a review. *Genes, 11*(12), 1456.

[48] Waring, R. H. (2020). Cytochrome P450: genotype to phenotype. *Xenobiotica, 50*(1), 9-18.

[49] Washington, V., Franklin, J. B., Huang, E. S., Mega, J. L., & Abernethy, A. P. (2023). Diversity, equity, and inclusion in clinical research: a path toward precision health for everyone. *Clinical Pharmacology & Therapeutics, 113*(3), 575-584.

[50] Winkler, E. C., & Knoppers, B. M. (2022). *Ethical challenges of precision cancer medicine.* Paper presented at the Seminars in cancer biology.

[51] Wright, C. J., Smith, C. W., & Jiggins, C. D. (2022). Alternative splicing as a source of phenotypic diversity. *Nature Reviews Genetics, 23*(11), 697-710.

[52] Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., . . . He, L. (2021). Cytochrome P450 enzymes and drug metabolism in humans. *International journal of molecular sciences, 22*(23), 12808.